HCC CONNECT review paper published in Liver Cancer

Dr Mohamed Bouattour is a physician in the Department of Digestive Oncology and Consultant in the Department of Hepatology at Beaujon University Hospital and has held this these positions since November 2007. He is board certified in Gastroenterology-Hepatology and Medical Oncology. He has expertise in the field of liver tumours, hepatocellular carcinoma, and pre-clinical and clinical research for liver disease. Dr Bouattour works in close collaboration with a multidisciplinary team including, liver surgeons, radiologists, oncologists, hepatologists and pathologists, to improve the management of patients with liver cancers. Dr Bouattour has been involved in presenting several collaborative works in national and international scientific meetings. He has authored and co-authored scientific papers in the field of liver and cancer diseases. He is investigator and sub investigator for several phase 1, 2 and 3 clinical trials. Dr Bouattour is member of several national and international societies such as the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL), the International Liver Cancer Association (ILCA) and the American Society of Clinical Oncology (ASCO). Relevant Publications Coriat R, Faivre SJ, Mir O, Dreyer C, Ropert S, Bouattour M, Desjardins R, Goldwasser F, Raymond E. Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study. Int J Nanomedicine 2016; 21; 11: 6207-6216. Bouattour M, Soubrane O, de Gramont A, Faivre S. Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM. Trials 2016; 25; 17(1): 563. Bouattour M, Payancé A, Wassermann J. Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging. World J Hepatol 2015; 7(20):2245-63. Bouattour M, Rousseau B, Wassermann J, Payancé A, Huillard O. Negative Trials for Foreseeable Safety Reasons in Advanced Hepatocellular Carcinoma: How Long Are We Going to Take Lightly Pharmacokinetics of Tyrosine Kinase Inhibitors? J Clin Oncol 2015; 33(22): 2484-5. Dreyer C, Sablin MP, Bouattour M, Neuzillet C, Ronot M, Dokmak S, Belghiti J, Guedj N, Paradis V, Raymond E, Faivre S. Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy. World J Hepatol 2015; 7(6): 910-5. Patrikidou A, Sinapi I, Regnault H, Fayard F, Bouattour M, Fartoux L, Faivre S, Malka D, Ducreux M, Boige V. Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies. Invest New Drugs 2014; 32(5): 1028-35. Ronot M, Bouattour M, Wassermann J, Bruno O, Dreyer C, Larroque B, Castera L, Vilgrain V, Belghiti J, Raymond E, Faivre S. Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncologist 2014; (4): 394-402. Ozenne V, Bouattour M, Goutté N, Vullierme MP, Ripault MP, Castelnau C, Valla DC, Degos F, Farges O. Prospective evaluation of the management of hepatocellular carcinoma in the elderly. Dig Liver Dis 2011; 43(12):1001-5.

Dr Neil Mehta underwent medical training at the University of California, San Francisco (UCSF). He was an Intern then a Resident at the Hospital of the University of Pennsylvania before becoming a Fellow in Gastroenterology and Transplant Hepatology at UCSF. He is Associate Professor in Medicine at UCSF and has held this position since 2013. He is specifically interested in issues related to the diagnosis and management of patients with hepatocellular carcinoma (HCC) particularly with regards to outcomes in liver transplantation.

Aiwu Ruth He, MD, PhD is a Professor of Medicine at Columbia University Medical Center. She earned her MD from the Xiangya School of Medicine at Central South University and her PhD in Biochemistry from East Carolina University’s Brody School of Medicine. Dr He completed her postdoctoral training at the National Institutes of Health under the mentorship of Dr Simeon Taylor, followed by an internal medicine residency at the Brody School of Medicine and a Hematology/Oncology fellowship at Georgetown University Hospital.

Dr He is a recognized leader in liver cancer research and patient care, with a primary focus on developing innovative therapeutics for hepatocellular carcinoma (HCC) and biliary tract cancer (BTC). 

She is deeply committed to a programmatic, multidisciplinary approach to clinical practice, ensuring optimal outcomes for her patients across the continuum of care.

Outside of her clinical duties, Dr He serves as the Director of Hepatobiliary Cancers in the Department of Medicine, Division of Hematology and Oncology, as well as the Director of Liver Transplant Oncology at the Center for Liver Disease and Transplantation. In these roles, she oversees clinical research on hepatobiliary cancers.

For a list of publications, please visit:

https://pubmed.ncbi.nlm.nih.gov/?term=he%2C+AR+or+He%2C+aiwu

Dr Emil Cohen completed medical training at George Washington University Medical School and then went on to an Internship at Washington Hospital Center. He completed residencies and fellowships in the Department of Radiology at the Mount Sinai Medical Center in New York. He is currently Associate Professor in the Department of Radiology at Georgetown University Hospital in Washington DC. Dr Cohen has been an investigator and co-investigator on two international clinical trials for hepatocellular carcinoma.

Relevant publications

Gaba RC, Lewandowski RJ, Hickey R, Baerlocher MO, Cohen EI, Dariushnia SR, d’Othée BJ, Padia SA, Salem R, Wang DS, Nikolic B. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol 2016 Apr; 27(4): 457-73.

McWilliams JP, Kuo MD, Rose SC, Bagla S, Caplin DM, Cohen EI, Faintuch S, Spies JB, Saad WE, Nikolic B. Society of interventional radiology position statement: prostate artery embolization for treatment of benign disease of the prostate. J Vasc Interv Radiol 2014; 25: 1349–1351.

Franklin BR, Patel KM, Nahabedian MY, Baldassari LE, Cohen EI, Bhanot P. Predicting abdominal closure after component separation for complex ventral hernias: maximizing the use of preoperative computed tomography. Ann Plast Surg 2013; 71: 261–265.

Lee JS, Patel KM, Zou Z, Prince MR, Cohen EI. Computerized tomographic and magnetic resonance angiography for perforator-based free flaps: technical considerations. Clinics in Plastic Surgery 2011; 38: 219–228.

Stanca CM, Fiel MI, Aledort L, Cohen E, del Rio Martin J, Schiano TD. Factors associated with persistent thrombocytopenia after liver transplantation. Transplant Proc 2010; 42: 1769–1773.

Aidi HE, Mani V, Weinshelbaum KB, Aguiar SH, Taniguchi H, Postley JE, Samber DD, Cohen EI, Stern J, van der Geest RJ, Reiber JH, Woodward M, Fuster V, Gidding SS, Fayad ZA. Cross-sectional, prospective study of MRI reproducibility in the assessment of plaque burden of the carotid arteries and aorta. Nat Clin Pract Cardiovasc Med 2009 Mar; 6(3): 219-28. doi: 10.1038/ncpcardio1444. Epub 2009 Jan 27.

Lim KH, Ward SC, Roayaie S, Cohen E, Schwartz M, Fiel MI, Thung SN. Multiple inflammatory and serum amyloid a positive telangiectatic hepatic adenomas with glycogenated nuclei arising in a background of nonalcoholic steatohepatitis. Semin Liver Dis 2008 Nov; 28(4): 434-439.

Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown RS Jr, Rafii S, Schwartz JD. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008 Jun 20; 26(18): 2992-2998.

Cohen EI, Kelly SA, Edye M, Mitty HA, Bromberg JS. MRI estimation of total renal volume demonstrates significant association with healthy donor weight. Eur J Radiol 2009 Aug; 71(2): 283-287.

Cohen EI, Weinreb DB, Siegelbaum RH, Honig S, Marin M, Weintraub JL, Lookstein RA. Time resolved magnetic resonance angiography for the classification of endoleaks after endovascular aneurysm repair. J Magn Reson Imaging 2008 Mar; 27(3): 500-503.

Emre S, Arnon R, Cohen E, Morotti RA, Vaysman D, Shneider BL. Resolution of hepatopulmonary syndrome after auxiliary partial orthotopic liver transplantation in abernethy malformation. A case report. Liver Transpl 2007; 13: 1662-1668.

Talenfeld AD, Schwope RB, Alper HJ, Cohen EI, Lookstein RA. MDCT angiography of the renal arteries in patients with atherosclerotic renal artery stenosis: implications for renal artery stenting with distal protection. AJR Am J Roentgenol 2007; 188: 1652-1658.

Schwope RB, Alper HJ, Talenfeld AD, Cohen EI, Lookstein RA. MR angiography for patient surveillance after endovascular repair of abdominal aortic aneurysms. AJR Am J Roentgenol 2007; 188(4): W334-340.

Xu R, Bu-Ghanim M, Fiel M, Schiano T, Cohen E, Thung S. Hepatocellular carcinoma associated with an atypical presentation of Wilson's Disease. Semin Liver Dis 2007; 27(1): 124-127.

Levi G, Moueen B, Xu R, Cohen E, Abittan C, Roayaie S. 48 year-old obese man with a 3 cm liver lesion and a history of hemochromatosis and lymphoma. Semin Liver Dis 2004; 24(3): 327-332. Cohen EI, Wilck E, Shapiro R. Hepatic imaging in the 21st Century. Semin Liver Dis 2006; 26: 363–372.

Dr Mohamed Bouattour is a physician in the Department of Digestive Oncology and Consultant in the Department of Hepatology at Beaujon University Hospital and has held this these positions since November 2007. He is board certified in Gastroenterology-Hepatology and Medical Oncology. He has expertise in the field of liver tumours, hepatocellular carcinoma, and pre-clinical and clinical research for liver disease. Dr Bouattour works in close collaboration with a multidisciplinary team including, liver surgeons, radiologists, oncologists, hepatologists and pathologists, to improve the management of patients with liver cancers. Dr Bouattour has been involved in presenting several collaborative works in national and international scientific meetings. He has authored and co-authored scientific papers in the field of liver and cancer diseases. He is investigator and sub investigator for several phase 1, 2 and 3 clinical trials. Dr Bouattour is member of several national and international societies such as the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL), the International Liver Cancer Association (ILCA) and the American Society of Clinical Oncology (ASCO). Relevant Publications Coriat R, Faivre SJ, Mir O, Dreyer C, Ropert S, Bouattour M, Desjardins R, Goldwasser F, Raymond E. Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study. Int J Nanomedicine 2016; 21; 11: 6207-6216. Bouattour M, Soubrane O, de Gramont A, Faivre S. Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM. Trials 2016; 25; 17(1): 563. Bouattour M, Payancé A, Wassermann J. Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging. World J Hepatol 2015; 7(20):2245-63. Bouattour M, Rousseau B, Wassermann J, Payancé A, Huillard O. Negative Trials for Foreseeable Safety Reasons in Advanced Hepatocellular Carcinoma: How Long Are We Going to Take Lightly Pharmacokinetics of Tyrosine Kinase Inhibitors? J Clin Oncol 2015; 33(22): 2484-5. Dreyer C, Sablin MP, Bouattour M, Neuzillet C, Ronot M, Dokmak S, Belghiti J, Guedj N, Paradis V, Raymond E, Faivre S. Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy. World J Hepatol 2015; 7(6): 910-5. Patrikidou A, Sinapi I, Regnault H, Fayard F, Bouattour M, Fartoux L, Faivre S, Malka D, Ducreux M, Boige V. Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies. Invest New Drugs 2014; 32(5): 1028-35. Ronot M, Bouattour M, Wassermann J, Bruno O, Dreyer C, Larroque B, Castera L, Vilgrain V, Belghiti J, Raymond E, Faivre S. Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncologist 2014; (4): 394-402. Ozenne V, Bouattour M, Goutté N, Vullierme MP, Ripault MP, Castelnau C, Valla DC, Degos F, Farges O. Prospective evaluation of the management of hepatocellular carcinoma in the elderly. Dig Liver Dis 2011; 43(12):1001-5.

Dr Neil Mehta underwent medical training at the University of California, San Francisco (UCSF). He was an Intern then a Resident at the Hospital of the University of Pennsylvania before becoming a Fellow in Gastroenterology and Transplant Hepatology at UCSF. He is Associate Professor in Medicine at UCSF and has held this position since 2013. He is specifically interested in issues related to the diagnosis and management of patients with hepatocellular carcinoma (HCC) particularly with regards to outcomes in liver transplantation.

Aiwu Ruth He, MD, PhD is a Professor of Medicine at Columbia University Medical Center. She earned her MD from the Xiangya School of Medicine at Central South University and her PhD in Biochemistry from East Carolina University’s Brody School of Medicine. Dr He completed her postdoctoral training at the National Institutes of Health under the mentorship of Dr Simeon Taylor, followed by an internal medicine residency at the Brody School of Medicine and a Hematology/Oncology fellowship at Georgetown University Hospital.

Dr He is a recognized leader in liver cancer research and patient care, with a primary focus on developing innovative therapeutics for hepatocellular carcinoma (HCC) and biliary tract cancer (BTC). 

She is deeply committed to a programmatic, multidisciplinary approach to clinical practice, ensuring optimal outcomes for her patients across the continuum of care.

Outside of her clinical duties, Dr He serves as the Director of Hepatobiliary Cancers in the Department of Medicine, Division of Hematology and Oncology, as well as the Director of Liver Transplant Oncology at the Center for Liver Disease and Transplantation. In these roles, she oversees clinical research on hepatobiliary cancers.

For a list of publications, please visit:

https://pubmed.ncbi.nlm.nih.gov/?term=he%2C+AR+or+He%2C+aiwu

Dr Emil Cohen completed medical training at George Washington University Medical School and then went on to an Internship at Washington Hospital Center. He completed residencies and fellowships in the Department of Radiology at the Mount Sinai Medical Center in New York. He is currently Associate Professor in the Department of Radiology at Georgetown University Hospital in Washington DC. Dr Cohen has been an investigator and co-investigator on two international clinical trials for hepatocellular carcinoma.

Relevant publications

Gaba RC, Lewandowski RJ, Hickey R, Baerlocher MO, Cohen EI, Dariushnia SR, d’Othée BJ, Padia SA, Salem R, Wang DS, Nikolic B. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol 2016 Apr; 27(4): 457-73.

McWilliams JP, Kuo MD, Rose SC, Bagla S, Caplin DM, Cohen EI, Faintuch S, Spies JB, Saad WE, Nikolic B. Society of interventional radiology position statement: prostate artery embolization for treatment of benign disease of the prostate. J Vasc Interv Radiol 2014; 25: 1349–1351.

Franklin BR, Patel KM, Nahabedian MY, Baldassari LE, Cohen EI, Bhanot P. Predicting abdominal closure after component separation for complex ventral hernias: maximizing the use of preoperative computed tomography. Ann Plast Surg 2013; 71: 261–265.

Lee JS, Patel KM, Zou Z, Prince MR, Cohen EI. Computerized tomographic and magnetic resonance angiography for perforator-based free flaps: technical considerations. Clinics in Plastic Surgery 2011; 38: 219–228.

Stanca CM, Fiel MI, Aledort L, Cohen E, del Rio Martin J, Schiano TD. Factors associated with persistent thrombocytopenia after liver transplantation. Transplant Proc 2010; 42: 1769–1773.

Aidi HE, Mani V, Weinshelbaum KB, Aguiar SH, Taniguchi H, Postley JE, Samber DD, Cohen EI, Stern J, van der Geest RJ, Reiber JH, Woodward M, Fuster V, Gidding SS, Fayad ZA. Cross-sectional, prospective study of MRI reproducibility in the assessment of plaque burden of the carotid arteries and aorta. Nat Clin Pract Cardiovasc Med 2009 Mar; 6(3): 219-28. doi: 10.1038/ncpcardio1444. Epub 2009 Jan 27.

Lim KH, Ward SC, Roayaie S, Cohen E, Schwartz M, Fiel MI, Thung SN. Multiple inflammatory and serum amyloid a positive telangiectatic hepatic adenomas with glycogenated nuclei arising in a background of nonalcoholic steatohepatitis. Semin Liver Dis 2008 Nov; 28(4): 434-439.

Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown RS Jr, Rafii S, Schwartz JD. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008 Jun 20; 26(18): 2992-2998.

Cohen EI, Kelly SA, Edye M, Mitty HA, Bromberg JS. MRI estimation of total renal volume demonstrates significant association with healthy donor weight. Eur J Radiol 2009 Aug; 71(2): 283-287.

Cohen EI, Weinreb DB, Siegelbaum RH, Honig S, Marin M, Weintraub JL, Lookstein RA. Time resolved magnetic resonance angiography for the classification of endoleaks after endovascular aneurysm repair. J Magn Reson Imaging 2008 Mar; 27(3): 500-503.

Emre S, Arnon R, Cohen E, Morotti RA, Vaysman D, Shneider BL. Resolution of hepatopulmonary syndrome after auxiliary partial orthotopic liver transplantation in abernethy malformation. A case report. Liver Transpl 2007; 13: 1662-1668.

Talenfeld AD, Schwope RB, Alper HJ, Cohen EI, Lookstein RA. MDCT angiography of the renal arteries in patients with atherosclerotic renal artery stenosis: implications for renal artery stenting with distal protection. AJR Am J Roentgenol 2007; 188: 1652-1658.

Schwope RB, Alper HJ, Talenfeld AD, Cohen EI, Lookstein RA. MR angiography for patient surveillance after endovascular repair of abdominal aortic aneurysms. AJR Am J Roentgenol 2007; 188(4): W334-340.

Xu R, Bu-Ghanim M, Fiel M, Schiano T, Cohen E, Thung S. Hepatocellular carcinoma associated with an atypical presentation of Wilson's Disease. Semin Liver Dis 2007; 27(1): 124-127.

Levi G, Moueen B, Xu R, Cohen E, Abittan C, Roayaie S. 48 year-old obese man with a 3 cm liver lesion and a history of hemochromatosis and lymphoma. Semin Liver Dis 2004; 24(3): 327-332. Cohen EI, Wilck E, Shapiro R. Hepatic imaging in the 21st Century. Semin Liver Dis 2006; 26: 363–372.

Dr Mohamed Bouattour is a physician in the Department of Digestive Oncology and Consultant in the Department of Hepatology at Beaujon University Hospital and has held this these positions since November 2007. He is board certified in Gastroenterology-Hepatology and Medical Oncology. He has expertise in the field of liver tumours, hepatocellular carcinoma, and pre-clinical and clinical research for liver disease. Dr Bouattour works in close collaboration with a multidisciplinary team including, liver surgeons, radiologists, oncologists, hepatologists and pathologists, to improve the management of patients with liver cancers. Dr Bouattour has been involved in presenting several collaborative works in national and international scientific meetings. He has authored and co-authored scientific papers in the field of liver and cancer diseases. He is investigator and sub investigator for several phase 1, 2 and 3 clinical trials. Dr Bouattour is member of several national and international societies such as the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL), the International Liver Cancer Association (ILCA) and the American Society of Clinical Oncology (ASCO). Relevant Publications Coriat R, Faivre SJ, Mir O, Dreyer C, Ropert S, Bouattour M, Desjardins R, Goldwasser F, Raymond E. Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study. Int J Nanomedicine 2016; 21; 11: 6207-6216. Bouattour M, Soubrane O, de Gramont A, Faivre S. Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM. Trials 2016; 25; 17(1): 563. Bouattour M, Payancé A, Wassermann J. Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging. World J Hepatol 2015; 7(20):2245-63. Bouattour M, Rousseau B, Wassermann J, Payancé A, Huillard O. Negative Trials for Foreseeable Safety Reasons in Advanced Hepatocellular Carcinoma: How Long Are We Going to Take Lightly Pharmacokinetics of Tyrosine Kinase Inhibitors? J Clin Oncol 2015; 33(22): 2484-5. Dreyer C, Sablin MP, Bouattour M, Neuzillet C, Ronot M, Dokmak S, Belghiti J, Guedj N, Paradis V, Raymond E, Faivre S. Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy. World J Hepatol 2015; 7(6): 910-5. Patrikidou A, Sinapi I, Regnault H, Fayard F, Bouattour M, Fartoux L, Faivre S, Malka D, Ducreux M, Boige V. Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies. Invest New Drugs 2014; 32(5): 1028-35. Ronot M, Bouattour M, Wassermann J, Bruno O, Dreyer C, Larroque B, Castera L, Vilgrain V, Belghiti J, Raymond E, Faivre S. Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncologist 2014; (4): 394-402. Ozenne V, Bouattour M, Goutté N, Vullierme MP, Ripault MP, Castelnau C, Valla DC, Degos F, Farges O. Prospective evaluation of the management of hepatocellular carcinoma in the elderly. Dig Liver Dis 2011; 43(12):1001-5.

Dr Neil Mehta underwent medical training at the University of California, San Francisco (UCSF). He was an Intern then a Resident at the Hospital of the University of Pennsylvania before becoming a Fellow in Gastroenterology and Transplant Hepatology at UCSF. He is Associate Professor in Medicine at UCSF and has held this position since 2013. He is specifically interested in issues related to the diagnosis and management of patients with hepatocellular carcinoma (HCC) particularly with regards to outcomes in liver transplantation.

Aiwu Ruth He, MD, PhD is a Professor of Medicine at Columbia University Medical Center. She earned her MD from the Xiangya School of Medicine at Central South University and her PhD in Biochemistry from East Carolina University’s Brody School of Medicine. Dr He completed her postdoctoral training at the National Institutes of Health under the mentorship of Dr Simeon Taylor, followed by an internal medicine residency at the Brody School of Medicine and a Hematology/Oncology fellowship at Georgetown University Hospital.

Dr He is a recognized leader in liver cancer research and patient care, with a primary focus on developing innovative therapeutics for hepatocellular carcinoma (HCC) and biliary tract cancer (BTC). 

She is deeply committed to a programmatic, multidisciplinary approach to clinical practice, ensuring optimal outcomes for her patients across the continuum of care.

Outside of her clinical duties, Dr He serves as the Director of Hepatobiliary Cancers in the Department of Medicine, Division of Hematology and Oncology, as well as the Director of Liver Transplant Oncology at the Center for Liver Disease and Transplantation. In these roles, she oversees clinical research on hepatobiliary cancers.

For a list of publications, please visit:

https://pubmed.ncbi.nlm.nih.gov/?term=he%2C+AR+or+He%2C+aiwu

Dr Emil Cohen completed medical training at George Washington University Medical School and then went on to an Internship at Washington Hospital Center. He completed residencies and fellowships in the Department of Radiology at the Mount Sinai Medical Center in New York. He is currently Associate Professor in the Department of Radiology at Georgetown University Hospital in Washington DC. Dr Cohen has been an investigator and co-investigator on two international clinical trials for hepatocellular carcinoma.

Relevant publications

Gaba RC, Lewandowski RJ, Hickey R, Baerlocher MO, Cohen EI, Dariushnia SR, d’Othée BJ, Padia SA, Salem R, Wang DS, Nikolic B. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol 2016 Apr; 27(4): 457-73.

McWilliams JP, Kuo MD, Rose SC, Bagla S, Caplin DM, Cohen EI, Faintuch S, Spies JB, Saad WE, Nikolic B. Society of interventional radiology position statement: prostate artery embolization for treatment of benign disease of the prostate. J Vasc Interv Radiol 2014; 25: 1349–1351.

Franklin BR, Patel KM, Nahabedian MY, Baldassari LE, Cohen EI, Bhanot P. Predicting abdominal closure after component separation for complex ventral hernias: maximizing the use of preoperative computed tomography. Ann Plast Surg 2013; 71: 261–265.

Lee JS, Patel KM, Zou Z, Prince MR, Cohen EI. Computerized tomographic and magnetic resonance angiography for perforator-based free flaps: technical considerations. Clinics in Plastic Surgery 2011; 38: 219–228.

Stanca CM, Fiel MI, Aledort L, Cohen E, del Rio Martin J, Schiano TD. Factors associated with persistent thrombocytopenia after liver transplantation. Transplant Proc 2010; 42: 1769–1773.

Aidi HE, Mani V, Weinshelbaum KB, Aguiar SH, Taniguchi H, Postley JE, Samber DD, Cohen EI, Stern J, van der Geest RJ, Reiber JH, Woodward M, Fuster V, Gidding SS, Fayad ZA. Cross-sectional, prospective study of MRI reproducibility in the assessment of plaque burden of the carotid arteries and aorta. Nat Clin Pract Cardiovasc Med 2009 Mar; 6(3): 219-28. doi: 10.1038/ncpcardio1444. Epub 2009 Jan 27.

Lim KH, Ward SC, Roayaie S, Cohen E, Schwartz M, Fiel MI, Thung SN. Multiple inflammatory and serum amyloid a positive telangiectatic hepatic adenomas with glycogenated nuclei arising in a background of nonalcoholic steatohepatitis. Semin Liver Dis 2008 Nov; 28(4): 434-439.

Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown RS Jr, Rafii S, Schwartz JD. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008 Jun 20; 26(18): 2992-2998.

Cohen EI, Kelly SA, Edye M, Mitty HA, Bromberg JS. MRI estimation of total renal volume demonstrates significant association with healthy donor weight. Eur J Radiol 2009 Aug; 71(2): 283-287.

Cohen EI, Weinreb DB, Siegelbaum RH, Honig S, Marin M, Weintraub JL, Lookstein RA. Time resolved magnetic resonance angiography for the classification of endoleaks after endovascular aneurysm repair. J Magn Reson Imaging 2008 Mar; 27(3): 500-503.

Emre S, Arnon R, Cohen E, Morotti RA, Vaysman D, Shneider BL. Resolution of hepatopulmonary syndrome after auxiliary partial orthotopic liver transplantation in abernethy malformation. A case report. Liver Transpl 2007; 13: 1662-1668.

Talenfeld AD, Schwope RB, Alper HJ, Cohen EI, Lookstein RA. MDCT angiography of the renal arteries in patients with atherosclerotic renal artery stenosis: implications for renal artery stenting with distal protection. AJR Am J Roentgenol 2007; 188: 1652-1658.

Schwope RB, Alper HJ, Talenfeld AD, Cohen EI, Lookstein RA. MR angiography for patient surveillance after endovascular repair of abdominal aortic aneurysms. AJR Am J Roentgenol 2007; 188(4): W334-340.

Xu R, Bu-Ghanim M, Fiel M, Schiano T, Cohen E, Thung S. Hepatocellular carcinoma associated with an atypical presentation of Wilson's Disease. Semin Liver Dis 2007; 27(1): 124-127.

Levi G, Moueen B, Xu R, Cohen E, Abittan C, Roayaie S. 48 year-old obese man with a 3 cm liver lesion and a history of hemochromatosis and lymphoma. Semin Liver Dis 2004; 24(3): 327-332. Cohen EI, Wilck E, Shapiro R. Hepatic imaging in the 21st Century. Semin Liver Dis 2006; 26: 363–372.